| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12094-010-0504-X |
| P698 | PubMed publication ID | 20462837 |
| P2093 | author name string | Alvarez I | |
| Martín M | |||
| Rodríguez C | |||
| Gascón P | |||
| Muñoz M | |||
| Adrover E | |||
| Alba E | |||
| Albanell J | |||
| Barnadas A | |||
| Calvo L | |||
| Colomer R | |||
| Fernández Y | |||
| García Mata J | |||
| García-Estévez L | |||
| Llombart A | |||
| Lluch A | |||
| Margueli M | |||
| Rodríguez Lescure A | |||
| Seguí MA | |||
| Tusquets I | |||
| P2860 | cites work | Molecular portraits of human breast tumours | Q28032461 |
| Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study | Q28281843 | ||
| Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial | Q28289262 | ||
| A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer | Q28297827 | ||
| Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy | Q28300092 | ||
| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
| Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data | Q33285612 | ||
| Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer | Q33852049 | ||
| Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer | Q33996115 | ||
| Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors | Q34190883 | ||
| Concordance among gene-expression-based predictors for breast cancer | Q34555829 | ||
| Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer | Q34601123 | ||
| The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer | Q34655437 | ||
| HER-2 and topoisomerase II as predictors of response to chemotherapy | Q34747499 | ||
| An attempt to clarify indications for hepatectomy for liver metastases from breast cancer | Q35057199 | ||
| Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor | Q36449271 | ||
| Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation | Q36954735 | ||
| HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. | Q38302227 | ||
| Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy | Q39785729 | ||
| Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colo | Q40477055 | ||
| Breast cancer molecular subtypes respond differently to preoperative chemotherapy | Q42482998 | ||
| Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial | Q44515895 | ||
| Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer | Q44902909 | ||
| Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast. | Q46002278 | ||
| Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast | Q46444191 | ||
| Association of surgery with improved survival in stage IV breast cancer patients | Q46625611 | ||
| Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis | Q46748090 | ||
| Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials | Q46828225 | ||
| Surgery for metastases to the brain | Q49096617 | ||
| Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. | Q50628426 | ||
| Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. | Q50648630 | ||
| Is liver resection justified for patients with hepatic metastases from breast cancer? | Q51775751 | ||
| A comparison of quality of life, disease impact and risk perception in women with invasive breast cancer and ductal carcinoma in situ. | Q51909368 | ||
| Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases. | Q53311270 | ||
| HER2 and Response to Paclitaxel in Node-Positive Breast Cancer | Q57578418 | ||
| Uncertain benefit from surgery in patients with lung metastases from breast carcinoma | Q62785649 | ||
| Acute Myeloid Leukemia After Adjuvant Breast Cancer Therapy in Older Women: Understanding Risk | Q63365930 | ||
| Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast Carcinoma | Q63365939 | ||
| A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer | Q73041014 | ||
| Ductal carcinoma in situ of the breast results of conservative and radical treatments in 716 patients | Q77225310 | ||
| Does aggressive local therapy improve survival in metastatic breast cancer? | Q78449283 | ||
| Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial | Q79803594 | ||
| Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system | Q80358653 | ||
| ErbB-dependent signaling as a determinant of trastuzumab resistance | Q80798219 | ||
| Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001 | Q81638938 | ||
| Surgery for pulmonary nodules in breast cancer patients | Q81690428 | ||
| Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001 | Q83130027 | ||
| Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis | Q83349364 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 278-286 | |
| P577 | publication date | 2010-04-01 | |
| P1433 | published in | Clinical and Translational Oncology | Q15754324 |
| P1476 | title | Current controversies in the management of breast cancer | |
| P478 | volume | 12 |
| Q44663629 | Factors associated with the development of chronic pain after surgery for breast cancer: a prospective cohort from a tertiary center in the United States. | cites work | P2860 |
Search more.